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Abstract: In an attempt for development of new antimicrobial agents; new series of chromen-2-one, pyrano[3,4-c]chromene and pyridino[3,4-
c]chromene derivatives bearing a diazo moiety were synthesized. Chromen-2-one derivatives were synthesized via treatment of 5-(aryldiazo) 
salicylaldehyde with different type of active methylene derivatives. Pyrano[3,4-c]chromene and pyridino[3,4-c]chromene derivatives were 
synthesized via treatment of chromen-2-one derivatives with another active methylene derivatives. The synthesized compounds were 
evaluated for their expected antimicrobial activity; where, the majority of these compounds showed potent antibacterial and antifungal 
activities against the tested strains of bacteria and fungi. 
 





ATURAL and synthetic chromen-2-one derivatives 
have great interest from medicinal chemists, many of 
the chromene derivatives used as precursors for the 
synthesis of potentially biologically active compounds.[1–5] 
Chromen-2-one moiety is being the parent scaffold in many 
of biological derivatives. Some of chromene skeleton are 
well established as antimicrobial agents such as Novobiocin 
and Chlorobiocin.[6] Recently, chromene derivatives have 
great interesting due to their potential application such as 
anti-HIV,[7] antitubercular,[8] antioxidant,[9] anticancer,[10] 
cytotoxic agents,[11] antidyslipidemic agent,[12] antileish-
manial,[13] anti-inflammatory agents.[14] 
Diazo compounds showed many valuable medicinal and 
pharmaceutical activities such as inhibition of RNA, DNA 
and carcinogenesis, protein synthesis and nitrogen fix-
ation.[15–18] 
 Bacterial and fungal resistance is one of the serious 
medical problems. Also, the levels rate of resistance is 
increasing to classical antibiotics. So, the development and 
discovery of effective antibacterial and antifungal drugs 
with novel mechanisms of action become urgent tasks for 
antimicrobial research programs.[19–22] 
 In light of these facts, the present study was 
designed to synthesize new chromene derivatives and 
evaluate their antimicrobial activity. As a trial to obtain 
novel class of antibacterial and antifungal agents, various 
groups were introduced into the target compounds 
 
RESULTS AND DISCUSSION 
Chemistry 
Treatment salicylaldehyde derivative 1[23] with ethyl 
acetoacetate in boiling EtOH/DMF led to the formation of 
chromen-2-one derivative 2 as yellow solid in high yield 
(Scheme 1). Its IR spectrum showed absorption bands at: 
1740, 1650 cm–1 corresponding to 2C=O functional groups. 
1H NMR revealed signals at: δ = 2.86 and 8.87 ppm cor-
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addition, the resulting chromene derivative was used for 
further chemical transformations as new routes for 
condensed chromene with possible biological activity. 
Acetylcoumarin derivative 2 was allowed to react with 
cyanoacetamide in presence of a catalytic amount of 
piperidine to give pyrano[3,4-c]chromene derivative 3. IR 
spectrum of compound 3 revealed absorption bands at: δ = 
3413 and 2209 cm–1 for the OH and cyano functional 
groups. Its 1H NMR spectrum showed two characterized 
signals at: δ = 2.50 and δ = 9.04 ppm assigned for the CH3 
and OH protons.  
 Reaction of acetylcoumarin derivative 2 with 2-
cyano-N-(furan-2-ylmethyl) acetamide[24] in the presence 
of few drops of piperidine under reflux yielded the 
corresponding pyrano[3,4-c]chromene derivative 4. IR 
spectrum of 4 showed absorption bands at: 3253, 2209 and 
1709 cm–1 corresponding to NH, C≡N and C=O functional 
groups, respectively. 1H NMR spectrum showed three 
signals at: δ = 2.57, 3.9 and 5.07 ppm due to CH3, CH2, and 
CH protons, respectively. Formation of 4 may be proceed 
through the addition of methylene group to the activated 
double bond of chromene to give Michael adduct, which 
cyclized to the respective pyrano[3,4-c]chromene 4 as a 
final product via elimination of water molecule. 
 Interaction of 1 with malononitrile in the presence of 
piperidine, 3-cyano chromane derivative 5 was obtained in 
good yield (Scheme 2). Its IR spectrum showed two 
characterized absorption bands at: 3348 and 2210 cm–1 
corresponding to NH and C≡N functional groups, 
respectively. Also, its 1H NMR assigned multiple signals in 
the region 7.54–8.25 for Ar-H with H-pyrane. In addition, 
interaction of compound 5 with malononitrile or ethyl 
acetoacetate in presence of catalytic amount piperidine 
afforded chromenylmalononitrile derivative 6 and 
chromenyl ethyl cyanoacetate derivative 7, respectively. 
Chromenylmalononitrile 6 can be prepared by treatment 
compound 1 with two moles of malononitrile. IR spectrum 
of 7 revealed the presence of cyano and carbonyl ester 
functional groups at: 2203 and 1737 cm–1, respectively. Its 
1H NMR spectrum displayed in addition to the aromatic 
proton signals, two doubles signals at: δ = 3.93 and 4.16 
ppm integrated for two protons due to the two CH protons. 
Moreover, its 13C NMR confirmed the structure. 
 Cyclocondensation of the salicylaldehyde derivative 
1 with diethyl malonate in presence of piperidine as 
catalyst afforded chromene-3-carboxylate derivative 8 as 
colored solid in high yield (Scheme 3). IR spectrum of 8 
revealed absorption band at: 1722 cm–1 attributed for C=O 
functional group. 1H NMR spectrum was characterized by 
the presence of triplet and quartet signals at: δ = 1.20 and 
4.29 ppm corresponding for ethyl protons. Iminochromene 
derivatives 9a and 9b were obtained through cyclocon-
densation of 1 with 2-cyano-N-(cyclohexyl)acetamide[25] 
and 2-cyano-N-(furan-3-ylmethyl)acetamide, respectively. 
IR spectrum of 9a exhibited strong absorption bands at 
3338 and 1672 cm–1 due to NH and C=O functional groups, 
respectively. Its 1H NMR showed signals at: δ = 0.80–1.06, 
2.65–2.71, 8.96 and 10.17 ppm corresponding to CH2 
cyclohexyl, CH–N cyclohexyl, NH and CONH protons, 
respectively. 
 On the same manner, interaction of 1 with 2-cyano-
N'-(4-methoxybenzylidene)acetohydrazide afforded the 
corresponding iminochromene derivative 10. IR spectrum 
of 10 showed bands for amino and carbonyl groups at: 3301 
and 1660 cm–1, respectively. 1H NMR spectrum displayed 
 
Scheme 1. Synthesis of pyrano[3,4-c]chromene derivatives 3 and 4. 
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two characterized singlet signals at: δ = 3.80 and 8.75 ppm 
corresponding for OCH3 and azomethine protons, respec-
tively. In addition, 13C NMR showed three signals at: 55.8, 
151.0 and 160.9 corresponding to OCH3, C=N and C=O 
carbons, respectively. 
 In addition, chromene-3-carboxamide 11 was 
obtained via interaction of 1 with cyanoacetamide in EtOH/ 
DMF containing catalytic amount of piperidine. 1H NMR 
spectrum of 11 afforded two broad signals at: δ = 8.62, 9.04 
ppm attributed to NH and NH2 protons. Reaction of 
chromene derivative 11 with malononitrile or acetyl-
acetone afforded products which formulated on the basis 
of elemental analysis and spectral data as chromeno-
pyridine derivatives 12 and 13, respectively (Scheme 4). 1H 
NMR spectrum of 12 exhibited two broad signals at: δ = 
4.31 and 9.54 ppm due to NH2 and NH protons, res-
pectively. 1H NMR spectrum of 13 exhibited signals at: δ = 
2.27, 2.47 and 8.70 ppm corresponding to CH3, COCH3 and 
NH protons, respectively. The formation of 12 and 13 is 
assumed through the Michael addition of the activated 
methylene group to the activated double bond in 
compound 11 to afford the acyclic Michael adduct that 
cyclized, then aromatized to yield the final products. 
 Finally, 2-iminochromene derivative 9b was utilized 
as a starting material for further reaction. Hence, reaction 
of 9b with malononitrile or ethyl cyanoacetate in presence 
of a catalytic amount of piperidine afforded pyridino[3,4-c]-
chromene derivatives 14 and 15 (Scheme 5). 
Antimicrobial activity 
 
ANTIBACTERIAL AND ANTIFUNGAL ACTIVITIES 
Fifteen test organisms representing three different 
microbial groups were used: Group 1: (Gram positive 
bacteria) Staphylococcus aureus (RCMB 010027), Stap-
hylococcus epidermidis (RCMB 010024), Streptococcus 
pyogenes (RCMB 010015), and Bacillis subtilis (RCMB 
010063); Group 2: (Gram negative bacteria) Proteous 
vulgaris (RCMB 010085), Klebsiella pneumonia (RCMB 
010093), Shigella ﬂexneri (RCMB 0100542) and Pseudo-
monas aeruginosa (RCMB 010043); Group 3: (Fungi) 
Aspergillus fumigates (RCMB 02564), Aspergillus clavatus 
 
Scheme 3. Synthesis of chromene derivatives 8–10. 
 
Scheme 4. Synthesis of pyridino[3,4-c]chromene derivatives 12 and 13. 
 
 
Scheme 5. Synthesis of pyridino[3,4-c]chromene 
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(RCMB02593), Candida albicans (RCMB 05035), and 
Penicillium marneffei (RCMB 01267). Agar-diffusion 
method[26] was used for the determination of the 
preliminary screening of antibacterial activity. The newly 
synthesized target compounds were evaluated against 
clinical isolates of standard strains of fungi by the broth 
dilution method according to NCCLs[27] Ampicillin, 
Gentamycin and Amphotericin B were used as reference 
drugs for Gram-positive bacteria, Gram-negative bacteria 
and fungi, respectively. The results were recorded for each 
tested compounds as the average diameter of inhibition zones 
of bacterial growth around the discs in mm. The inhibition zone 
diameters, attributed to the tested original concentration (5 
mg/mL) as a preliminary test, are shown in Table 1.  
 Concerning the antimicrobial activity of chromene 
derivatives 2, 5, 8, 9a,b, 10, 11, the results displayed those 
derivatives showed moderate to good activities against 
most of all the screened organisms. Using the general 
structure provided in Figure 1, certain aspects of the 
structure activity relationships for these compounds can be 
more clearly highlighted. 
 The results revealed that compound 2 showed 
antimicrobial activity nearly equipotent to the reference 
drug against all screened organisms. While compound 8 
showed antimicrobial activity nearly equipotent to the 
reference drug only against gram –ve bacteria. Chromen-2-
one 5, 9a,b, 10 and 11; X was NH group and R were cyano 
or carboxamide derivatives. Regarding the effect of R 
group, compound 5 showed high antimicrobial activity 
against all screened organisms. Compound 9b and 10 
showed good antimicrobial activities only against gram +ve 
bacteria. Compound 11 showed high antimicrobial activity 
only against gram –ve bacteria. Compound 9a showed high 
antimicrobial activity only against fungi. Using the general 
structure provided in Figure 1, compound 6 showed high 
antimicrobial activity against all screened bacteria while 
compound 7 showed good activity only against fungi. 
 Using the general structure provided in Figure 2, 
pyrano[3,4-c]chromene derivatives 3 and 4; R were 
hydroxyl group (3) or NHCH2furfuryl moiety (4). Regarding 
the effect of R group, pyrano[3,4-c]chromene 3 showed 
high antimicrobial activity against all screened bacteria. 
While, pyrano[3,4-c]chromene 4 showed moderate activity 
against most of tested organisms. 
 Concerning the antimicrobial activity of pyridino[3,4-c]-
chromene derivatives 12–15: The presence of pyridino[3,4-
c]chromene moiety resulted in the highest antimicrobial 
activity among all the compounds investigated in this study. 
The presence of pyridino[3,4-c]-chromene moiety exh-
ibited the highest antibacterial activity against most of  
the organisms; pyridino[3,4-c]-chromene moiety showed 
results greater than the reference drug against most of the 
Table 1. Antimicrobial activities of the synthesized compounds against the pathological Gram +ve bacteria, Gram –ve bacteria 
and fungi expressed as inhibition diameter zones in millimeters 
Compd. 
No. 
Gram +ve bacteria Gram –ve bacteria Fungi 
S. aureus S. epider. S. pyoge. B. subtili. P. vulga. K. pneu. S. Flexn. P. aerug. A. fumig. A. clavat. C. albic. P. neffei 
2 24.5±0.3 22.5±0.4 23.7±0.8 26.3±0.6 22.6±0.2 21.0±0.6 21.4±0.6 16.3±0.5 21.2±0.3 19.2±0.2 18.7±0.3 20.7±0.5 
3 25.6±0.5 22.4±0.5 21.4±0.2 28.6±0.5 20.2±0.3 23.4±0.5 22.4±0.3 15.0±0.2 19.5±0.3 18.8±0.3 16.5±0.4 19.8±0.3 
4 15.1±0.7 14.5±0.5 NA 13.1±0.3 12.3±0.2 13.5±0.5 NA NA 14.5±0.6 11.7±0.5 10.3±0.3 13.5±0.8 
5 24±0.5 20.9±0.6 18.9±0.3 24.8±0.2 21.2±0.7 22.8±0.2 21.6±0.5 16.8±0.6 20.4±0.6 18.9±0.3 21.9±0.6 20.2±0.3 
6 15.3±0.4 14.7±0.4 NA 17.2±0.2 13.2±0.3 15.2±0.3 12.5±0.5 NA 21.1±0.3 19.1±0.2 23.8±0.4 18.9±0.3 
7 27.8±0.2 23.2±0.5 23.2±0.3 27.9±0.4 21.2±0.7 23.8±0.3 22.9±0.3 16.6±0.4 14.2±0.5 12.6±0.2 NA 13.5±0.6 
8 17.2±0.4 14.2±0.2 NA 18.4±0.1 22.5±0.3 24.3±0.1 22.4±0.3 16.9±0.3 13.5±0.5 11.8±0.4 10.9±0.3 12.2±0.6 
9a 15.2±0.2 16.9±0.3 NA 17.1±0.2 12.5±0.5 13.9±0.4 11.9±0.3 NA 21.8±0.3 19.2±0.3 22.5±0.4 19.9±0.6 
9b 26.7±0.6 22.0±0.2 21.7±0.3 28.8±0.3 14.8±0.4 15.5±0.7 14.7±0.4 NA 14.2±0.3 15.1±0.3 NA 13.4±0.1 
10 24.3±0.5 23.3±0.5 24.2±0.3 28.3±0.5 14.2±0.6 12.6±0.4 11.5±0.6 NA 13.4±0.6 11.7±0.5 NA 16.8±0.2 
11 17.7±0.3 14.4±0.2 NA 16.5±0.4 21.5±0.2 23.3±0.6 21.4±0.6 15.2±0.5 19.9±0.4 20.0±0.4 23.0±0.2 20.2±0.5 
12 29.2±0.3 26.1±0.3 28.3±0.4 36.3±0.4 24.5±0.2 27.7±0.3 25.2±0.6 18.2±0.4 25.1±0.6 24.1±0.3 26.9±0.4 26.4±0.5 
13 30.0±0.5 28.2±0.5 28.5±0.3 32.9±0.3 23.8±0.2 28.2±0.3 25.5±0.3 19.4±0.4 24.8±0.6 22.5±0.6 27.3±0.6 23.6±0.5 
14 29.9±0.4 27.6±0.4 28.5±0.4 34.8±0.3 25.1±0.5 27.2±0.1 26.2±0.3 18.8±0.3 23.6±0.4 23.9±0.5 28.4±0.8 25.2±0.7 
15 29.5±0.7 26.8±0.4 27.5±0.4 35.7±0.7 25.9±0.1 29.2±0.2 26.2±0.6 17.8±0.4 23.9±0.3 22.7±0.2 28.4±0.2 24.9±0.4 
Ampicillin 28.9±1 25.4±0.1 26.4±0.3 34.6±0.3 ----- ----- ----- ----- ----- ----- ----- ----- 
Gentamycin ----- ----- ----- ----- 23.4±0.3 26.3±0.1 24.8±0.2 17.3±0.1 ----- ----- ----- ----- 
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organisms. Using the general structure provided in Figure 
2, a moderate difference in antimicrobial activity is noted 
between the tested pyridino[3,4-c]chromene derivatives, 
this indicate that the main effect related to the presence of 
the pyridino[3,4-c]chromene moiety. The comparison bet-
ween the antimicrobial activity of pyridino[3,4-c]chromene 
and standard reference drugs against the used Gram 
positive, Gram negative bacteria and fungi is represented 
graphically in Figure 3. 
 
MINIMUM INHIBITORY CONCENTRATIONS AGAINST 
GRAM POSITIVE BACTERIA, GRAM NEGATIVE BACTERIA 
AND FUNGI 
The minimal inhibitory concentrations (MICs) for the 
promising compounds were determined using twofold 
serial dilution method[27] MICs results (µg/mL) of the most 
promising derivatives 2, 3, 5, 6, 9a, and 11–15 are pres-
ented in Table 2. The majority of synthesized compounds 
showed varying degrees of inhibition against the test panel 
of species. 
 Pyridino[3,4-c]chromene 14 showed equipotent 
potency of standard drugs in inhibiting the growth of  
S. pyogenes (MIC 0.24 μg/mL), P. vulgaris (MIC 1.95 μg/mL), 
S. flexneri (MIC 0.48 μg/mL), A. clavatus (MIC 1.95 μg/mL) 
and P. Marneffei (MIC 1.95 μg/mL). Pyridino[3,4-c]-
chromene 14 displayed 50 % less activity compared to stan-
dard drugs against P. aeruginosa (MIC 62.5 μg/mL).  
 Chromen-2-one 11 showed equipotent potency of 
standard drugs in inhibiting the growth of S. flexneri (MIC 
0.48 μg/mL), P. aeruginosa (MIC 31.25 μg/mL) and  
P. Marneffei (MIC 1.95 μg/mL). Chromen-2-one 11 dis-
played 50 % less activity compared to standard drugs 
against S. pyogenes (MIC 0.48 μg/mL), P. vulgaris (MIC 3.9 
μg/mL), A. Fumigates (MIC 1.95 μg/mL), A. clavatus (MIC 
3.9 μg/mL) and C. albicans (MIC 0.48 μg/mL).  
 Pyridino[3,4-c]chromene 12 showed equipotent 
potency of standard drugs in inhibiting the growth of  
S. pyogenes (MIC 0.24 μg/mL) and P. vulgaris (MIC 1.95 
μg/mL). Pyridino[3,4-c]chromene 12 displayed 50 % less 
activity compared to standard drugs against S. epidermidis 
(MIC 0.97 μg/mL), K. pneumonia (MIC 0.48 μg/mL),  
P. aeruginosa (MIC 62.5 μg/mL), A. Fumigates (MIC 1.95 
μg/mL), A. clavatus (MIC 3.9 μg/mL) and P. Marneffei (MIC 
3.9 μg/mL). Pyridino[3,4-c]chromene 13 showed equipotent 
potency of standard drugs in inhibiting the growth of  
A. Fumigates (MIC 0.97 μg/mL) and P. Marneffei (MIC 1.95 
μg/mL). pyridino[3,4-c]chromene 13 displayed 50 % less 
activity compared to standard drugs against C. albicans 
(MIC 0.48 μg/mL).  
 Chromen-2-one 9a showed equipotent potency of 
standard drugs in inhibiting the growth of A. fumigates 
(MIC 0.97 μg/mL). Chromen-2-one derivative 9a displayed 
50 % less activity compared to standard drugs against  
S. pyogenes (MIC 0.48 μg/mL), P. vulgaris (MIC 3.9 μg/mL), P. 
aeruginosa (MIC 62.5 μg/mL), A. clavatus (MIC 3.9 μg/mL), C. 
albicans (MIC 0.48 μg/mL) and P. Marneffei (MIC 3.9 μg/mL). 
 Chromene 5 displayed 50 % less activity compared to 
standard drugs against S. epidermidis (MIC 0.24 μg/mL),  
P. vulgaris (MIC 3.9 μg/mL), K. pneumonia (MIC 0.48 μg/mL), 
A. clavatus (MIC 3.9 μg/mL) and P. Marneffei (MIC 3.9 μg/mL).  
 Chromene 2 displayed 50 % less activity compared to 
standard drugs against P. vulgaris (MIC 3.9 μg/mL) and P. 
Marneffei (MIC 3.9 μg/mL).T2 
 
CONCLUSION  
Chromen-2-one, pyrano[3,4-c]chromene and pyridino[3,4-c]-
chromene derivatives bearing a diazo moiety were synth-
esized in order to evaluate their antibacterial and 
antifungal activities. Regarding the effect of each derivative 
against bacterial and fungal strains, results of antimicrobial 
activity in this study revealed that: the majority of these 
 
Figure 3. The comparison between the antimicrobial 
activities of pyridino[3,4-c]chromene and standard drug 
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compounds showed potent antibacterial and antifungal 
activities against the tested strains of bacteria and fungi. 
Pyridino[3,4-c]chromene moiety resulted in the highest 
antimicrobial activity among all the compounds investigated in 
this study. Pyridino[3,4-c]chromene moiety showed results 
greater than the reference drug against most of the organisms.  
Experimental Section 
All melting points are recorded on digital Gallen Kamp MFB-
595 instrument and may be uncorrected. The IR spectra 
(KBr) (cm–1) were measured on a JASCO spectrophoto-
meter. 1H NMR spectra were recorded on Bruker spectro-
meters (at 500 MHz) and are reported relative to 
deuterated solvent signals in deuterated dimethylsulfoxide 
(DMSO-d6). 13C NMR spectra were recorded on Bruker 
Spectrometers (at 125 MHz) in deuterated dimethyl-
sulfoxide (DMSO-d6). The purity of the synthesized 
compounds was monitored by TLC. Elemental analyses 
were carried out by the Microanalytical Research Center, 
Faculty of Science, Cairo University. Analytical results for C, H 
and N were within –/+ 0.4 of the calculated values. The 
antimicrobial screening and minimal inhibitory concen-
trations of the tested compounds were carried out at the 
Regional Center for Mycology and Biotechnology, Al-Azhar 




Equimolar amounts of compound 1 (0.01 mol) and ethyl 
acetoacetate (0.01 mol) in a mixture of 15 mL EtOH and 5 
mL DMF was treated with few drops of piperidine. The 
reaction mixture was heated under reflux for 4 h, and then 
allowed to cool. The precipitate that formed was filtered, 
washed with ethanol, dried and crystallized from ethanol to 
give compound 2 as yellow crystals. Yield 85 %; m.p. 235–237 
°C; IR: ν/cm–1 = 1740, 1650 (2C=O); 1H NMR: δ/ppm = 2.86 (s, 
3H, CH3), 7.58-8.25 (m, 7H, Ar-H), 8.87 (s, 1H, CH–pyrane); 13C 
NMR: 29.3 (CH3), 118.0, 119.5, 122.2, 123.6, 124.4 (2C), 129.3 
(2C), 131.0, 136.1, 138.4, 150.2, 150.8, 155.7, 159.4, 188.7 
(C=O); MS: m/z = 326 (M+; 3.9), 170 (5.5), 153 (7.0), 127 (70.5), 
65 (77), 55 (100); Anal. Calcd. For C17H11ClN2O3 (326.74): C, 





Cyanoacetamide (0.01 mol) was added to a solution of 
compound 2 (0.01 mol) in mixture of 15 mL EtOH, 5 mL DMF 
and 3 drops of piperidine. The reaction mixture was heated 
under reflux for 4 hours and concentrated to its half-
volume. The solid product was filtered off and recrystallized 
from ethanol to give compound 3 as pale yellow crystals. 
Yield 70 %; m.p. 265–267 °C; IR: ν/cm–1 = 3413 (broad, OH), 
2925 (CH-aliphatic), 2209 (C≡N), 1671 (C=O); 1H NMR: 
δ/ppm = 2.5 (s, 3H, CH3), 5.06 (s, 1H, H-pyrane), 7.59–8.22 
(m, 7H, Ar-H), 9.04 (br, 1H, OH); 13C NMR: 18.0 (CH3), 52.1, 
106.7, 117.4, 121.4, 121.8, 124.4, 124.6, 125.0, 128.6, 
129.1, 130.2 (2C), 136.5, 149.4, 151.2, 152.8, 159.0, 162.3, 
185.2; Anal. Calc.: C20H12ClN3O4: C, 61.00; H, 3.07; N, 10.67; 





A mixture of 2 (0.01 mol) and 2-cyano-N-(furan-2-ylmethyl) 
acetamide (0.01 mol) in a mixture of 15 mL EtOH and 5 mL 
DMF containing a catalytic amount of piperidine was 
heated under reflux for 4 h, then left to cool. The solid 
product formed was filtrated off, washed with EtOH, dried, 
Table 2. Minimum inhibitory concentration (µg/mL) of the most potent synthesized compounds against the pathological 
organisms 
Compd. No. S. aureus S. epidermidis S. pyogenes B. subtilis P. vulgaris K. pneumonia S. flexneri P. aeruginosa A. fumigatus A. clavatus C. albicans P. marneffei 
2 0.97 15.63 3.9 1.95 3.9 1.95 3.9 125 3.9 15.63 31.25 3.9 
3 3.9 3.9 31.25 1.95 7.81 3.9 7.81 250 3.9 31.25 62.5 7.81 
5 0.24 0.24 3.9 0.06 3.9 0.48 3.9 500 15.63 3.9 31.25 3.9 
6 3.9 1.95 62.5 0.97 7.81 1.95 7.81 250 7.81 15.63 31.25 15.63 
9a 0.24 1.95 0.48 0.06 3.9 0.84 1.95 62.5 0.97 3.9 0.48 3.9 
11 0.97 1.95 0.48 0.06 3.9 1.95 0.48 31.25 1.95 3.9 0.48 1.95 
12 0.24 0.97 0.24 0.06 1.95 0.48 3.9 62.5 1.95 3.9 0.97 3.9 
13 3.9 62.5 125 62.5 7.81 1.95 3.9 250 0.97 7.81 0.48 1.95 
14 0.24 3.9 0.24 0.06 1.95 0.97 0.48 62.5 0.24 1.95 0.97 1.95 
15 3.9 62.5 31.25 125 7.81 3.9 15.63 250 62.5 7.81 62.5 125 
Ampicillin 0.06 0.48 0.24 0.007 ----- ----- ----- ----- ----- ----- ----- ----- 
Gentamycin ----- ----- ----- ----- 1.95 0.24 0.48 31.25 ----- ----- ----- ----- 
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and finally crystallized from EtOH/DMF to give compound 4 
as pale yellow crystals. Yield 60 %; m.p. 290–292 °C; IR: 
ν/cm–1 = 3253 (NH), 2925 (aliphatic CH), 2209 (C≡N), 1709 ( 
C=O); 1H NMR: δ/ppm = 2.57 (s, 3H, CH3), 3.9 (s, 2H, CH2), 
5.07 (s, 1H, H-4-pyrane), 5.15 (d, 1H, CH-furfuryl), 6.40 (d, 
1H, CH-furfuryl), 7.50-8.56 (m, 8H, 7Ar-H + CHO-furfuryl), 
9.6 (br, 1H, NH cancelled with D2O); 13C NMR: 17.3 (CH3), 
37.7 (CH2), 45.2 (CH), 106.0, 110.6, 111.4, 119.1, 120.4, 
121.8, 124.4 (2C), 124.9, 128.6 (2C), 129.1 (2C), 136.8, 
142.3, 145.8, 150.2, 151.2, 152.5, 159.3, 161.9, 176.6; Anal. 
Calc: C25H17ClN4O4 (472.89): C, 63.50; H, 3.62; N, 11.85; 




A mixture of compound 1 (0.01 mol), malononitrile (0.01 
mol) and drops of piperidine in a mixture of 15 mL EtOH and 
5 mL DMF was heated under reflux for 2 hours. The solid 
product formed on hot collected by filtration and recrys-
tallized from ethanol/DMF to give compound 5 as brown 
crystals. Yield 80 %; m.p. > 300 °C; IR: ν/cm–1 = 3348 (NH), 
2210 (C≡N); 1H NMR: δ/ppm = 7.54–7.78 (m, 3H, Ar-H), 
7.87-8.25 (m, 5H, Ar-H & H-pyrane), 9.53 (br, 1H, NH 
exchangeable with D2O); 13C NMR: 110.3, 112.7, 115.4, 
116.8, 117.5, 121.5, 123.6, 123.7, 124.4, 129.1, 136.5, 145.2, 
150.8, 156.5, 164.4; Anal. Calc. C16H9ClN4O (308.73): C, 62.25; 




Method A: A mixture of compound 1 (0.01 mol ), 
malononitrile (0.02 mol) in a mixture of 15 mL EtOH, 5 mL 
DMF and 3 drops of piperidine was heated under refluxed 
for 3 h. The solid product formed on hot, collected by 
filtration and recrystallized from ethanol as orange crystals. 
Yield 82 %. Method B: A mixture of compound 5 (0.01 mol), 
malononitrile (0.01 mol) in a mixture of 15 mL EtOH, 5 mL 
DMF and 3 drops of piperidine was heated under refluxed 
for 2 h. The solid product formed on hot, collected by 
filtration and recrystallized from ethanol as orange crystals. 
Yield 79 %; m.p. > 300 °C; IR: ν/cm–1 = 3335 (NH2), 2209 
(C≡N); 1H NMR: δ/ppm = 3.76 (d, 1H, J = 3.7 Hz, CH), 4.01 
(d, 1H, J = 3.7 Hz, pyrane-H-4), 6.57–7.88 (m, 7H, Ar-H), 9.53 
(br, 2H, NH2); 13C NMR: 50.1, 63.8, 113.7, 117.1, 118.4, 
121.1, 124.2, 124.4, 129.1, 130.3, 136.5, 146.1, 150.8, 
151.2, 176.3; Anal. Calc. C19H11ClN6O (374.79): C, 60.89; H, 
2.96; N, 22.42; Found: C, 60.46; H, 2.54; N, 22.42. 
 
SYNTHESIS OF ETHYL 2-(2-AMINO-6-((4-CHLORO–
PHENYL)DIAZENYL)-3-CYANO-4H-CHROMEN-4-YL)-2-
CYANOACETATE (7) 
A solution of compound 5 (0.01 mol) and ethyl cyano-
acetate (0.01 mol) in a mixture of 15 mL EtOH and 5 mL 
DMF and 0.5 mL of piperidine was heated under reflux for 
4 h. The solid that formed was filtered and recrystallized 
from ethanol as brown crystals. Yield 50 %; m.p. 250–
251°C; IR: ν/cm–1 = 3364, 3260 (NH2), 2990 (aliphatic CH), 
2203 (C≡N), 1737 (C=O ester); 1H NMR: δ/ppm = 1.07 (t, 
3H, J = 7.5 Hz, CH3), 3.93 (d, 1H, J = 3.8 Hz, CH), 4.16 (d, 
1H, J = 3.8 Hz, CH-pyrane), 4.21 (q, 2H, J = 7.5 Hz, CH2 
ester), 7.6–8.22 (m, 7H, Ar-H), 9.22 (br, 2H, NH2); 13C 
NMR: 14.8 (CH3), 39.4 (CH), 71.9 (CH), 60.5 (CH2), 118.4 
(C≡N), 118.8 (C≡N), 123.9, 124.8, 127.4, 130.2, 137.0, 
144.7, 148.9, 166.9 (C=O); Anal. Calc. C21H16ClN5O3 
(421.84): C, 59.79; H, 3.82; N, 16.60; Found: C, 59.45; H, 
3.64; N, 16.02. 
 
SYNTHESIS OF ETHYL 6-((4-CHLOROPHENYL)DIAZENYL)-2-
OXO-2H-CHROMENE-3-CARBOXYLATE (8) 
A mixture of compound 1 (0.01 mol), diethyl malonate 
(0.01 mol) and catalytic amount of piperidine in EtOH/DMF 
(15/5 mL) was heated under reflux for 3 h. The solid 
product was collected by filtration and recrystallized from 
ethanol as brown crystals. Yield 75 %; m.p. 265–267 °C; IR: 
ν/cm–1 = 2923 (CH-aliphatic), 1722 (C=O); 1H NMR: δ/ppm 
= 1.20 (t, 3H; J = 7.5 Hz, CH3), 4.29 (q, 2H, J = 7.5 Hz, CH2), 
7.59–8.20 (m, 8H, 7Ar-H & H-pyrane); 13C NMR: 15.4, 62.4, 
113.5, 118.3, 119.5, 117.8, 122.5, 123.0, 124.4, 129.1, 
136.5, 149.4, 150.8, 155.2, 156.2, 167.1; Anal. Calc. 
C18H13ClN2O4: C, 60.60; H, 3.67; N, 7.85. Found: C, 60.84; H, 




To a solution of 1 (0.01 mol), 2-cyano-N-(cyclohexyl)acet-
amide or 2-cyano-N-(furan-3-ylmethyl)acetamide (0.01 mol) 
in EtOH/DMF (15/5 mL) and catalytic amount of piperidine 
was heated under reflux for 4 h, then cooled and poured 
into ice water. The resulting solid was filtered off, washed 
with water, dried and crystalized from ethanol.  
 
6-((4-Chlorophenyl)diazenyl)-N-cyclohexyl-2-imino-2H-
chromene-3-carboxamide (9a): Pale yellow crystals. Yield 
65 %; m.p.130–132 °C; IR: ν/cm–1 = 3338 (NH), 2922, 2852 
(CH-aliph), 1672 (C=O); 1H NMR: δ/ppm = 0.8–1.06 (m, 10H, 
CH2 cyclohexyl), 2.65–2.71 (m, 1H, CH-N cyclohexyl), 7.57–
8.13 (m, 8H, Ar-H & H-pyrane), 8.96, 10.17 (2br, 2H, 2NH; 
cancelled with D2O); 13C NMR: 23.2, 24.7, 33.1, 49.4, 113.1, 
118.3, 120.5, 120.9, 124.1, 124.4, 128.7, 129.1, 137.5, 
146.2, 151.2, 157.0, 161.3, 164.4; Anal. Calc. C22H21ClN4O2 
(408.89): C, 64.62; H, 5.18; N, 13.70. Found: C, 64.85; H, 
5.33; N, 13.55. 
6-((4-Chlorophenyl)diazenyl)-N-(furan-2-ylmethyl)-2-
imino-2H-chromene-3-carboxamide (9b): Yellow crystals. 
Yield 78 %; m.p. 230–232 °C; IR: ν/cm–1 = 3310, 3202 (2NH), 
2928 (CH-aliph), 1670 (C=O); 1H NMR: δ/ppm = 4.30 (s, 2H, 
CH2), 6.39 (d, 1H, CH-furfuryl), 6.59 (d, 1H, CH-furfuryl), 
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10.17 (2br, 2H, 2NH cancelled with D2O); 13C NMR: 37.4, 
111.2, 111.9, 112.4, 116.2, 120.8, 121.4, 124.5, 125.2, 
128.2, 130.2, 136.5, 142.4, 145.8, 148.2, 151.8, 156.8, 
160.2, 164.3; Anal. Calc. C21H15ClN4O3 (406.83): C, 62.00; H, 





To a solution of compound 1 (0.01 mol) and 2-cyano-N'-(4-
methoxybenzylidene)acetohydrazide (0.01 mol) in 20 mL of 
EtOH/DMF (3/1), a catalytic amount of piperidine was 
added. The reaction mixture was heated under reflux for 3 
h. The solid product formed on hot, collected by filtration 
and recrystallized from ethanol/DMF as orange crystals. 
Yield 82 %; m.p. > 300 °C; IR: ν/cm–1 = 3301 (NH), 2931 (CH-
aliph), 1660 (C=O); 1H NMR: δ/ppm = 3.80 (s, 3H, OCH3), 
6.82-8.60 (m, 12H, Ar-H & pyrane), 8.75 (s, 1H, N=CH), 8.89, 
9.10 (2br, 2H, 2NH; cancelled with D2O); 13C NMR: 55.8 
(CH3), 114.5, 114.8, 114.9, 115.6, 124.2, 124.3, 124.3, 
124.6, 124.7, 128.9, 129.7, 129.7, 129.8, 129.9, 130.0, 
130.1, 130.4, 136.1, 151.0 (C=N), 160.9 (C=O); Anal. Calc. 
C24H18ClN5O3 (459.89): C, 62.68; H, 3.95; N, 15.23; Found: C, 




A solution of compound 1 (0.01 mol) and cyanoacetamide 
(0.01 mol) in 20 mL EtOH/DMF (3/1) containing 0.5 mL 
piperidine was heated under reflux for 4 h. The solid was 
filtered off and recrystallized from ethanol as pale yellow 
crystals. Yield 82 %; m.p. 270–272 °C; IR: ν/cm–1 = 3400 
(NH2+NH), 1651 (C=O); 1H NMR: δ/ppm = 7.11–8.04 (m, 8H, 
Ar-H & H-pyrane), 8.62 (br, 1H, NH cancelled with D2O), 
9.04 (br, 2H, CONH2 cancelled with D2O); 13C NMR: 113.2, 
117.3, 120.8, 121.0, 123.0, 124.8, 128.1, 129.8, 137.5, 
146.2, 151.2, 157.1, 165.5, 172.7; Anal. Calc. C16H11ClN4O2 
(326.74): C, 58.82; H, 3.39; N, 17.15. Found: C, 58.95; H, 





A mixture of 11 (0.01 mol) and malononitrile (0.01 mol) in 
20 mL EtOH/DMF (3/1) was heated under reflux for 4 h, 
then cooled and poured into ice water. The resulting solid 
was filtered off, washed with water, dried and purified by 
recrystallization from ethanol to give compound 12 as red 
crystals. Yield 50 %; m.p. >300 °C; IR: ν/cm–1 = 3438, 3349, 
3242, 3190 (NH2 & 2NH), 2211 (C≡N), 1642 (C=O); 1H NMR: 
δ/ppm = 4.31 (br, 2H, NH2), 7.61–8.13 (m, 7H, Ar-H), 9.53 
(br, 2H, 2NH cancelled with D2O); 13C NMR: 77.1, 112.5, 
113.4, 116.8, 121.5, 121.8, 123.6, 124.4, 129.1, 136.5, 
145.7, 151.2, 155, 156.5, 161.1, 162.3, 164.4; Anal. Calc: 
C19H11ClN6O2 (390.79): C, 58.40; H, 2.84; N, 21.51; Found: C, 





A mixture of 11 (0.01 mol) and acetyl acetone (0.01 mol) in 
20 mL EtOH/DMF (3/1) was heated under reflux for 4 h, 
then cooled and poured into ice water. The resulting solid 
was filtered off, washed with water, dried and purified by 
recrystallization from ethanol to give 13 as pall brown 
crystals. Yield 66 %; m.p. 140–142 °C; IR: ν/cm–1 = 3338 
(NH), 2929 (CH-aliph), 1742, 1664 (2C=O); 1H NMR: δ/ppm 
= 2.27 (s, 3H, CH3), 2.47 (s, 3H, CH3), 7.20–8.13 (m, 7H, Ar-
H), 8.7 (br, 2H, 2NH cancelled with D2O); 13C NMR: 21.7, 
32.6, 112.7, 113.7, 118.7, 121.5, 121.9, 123.6, 124.4, 129.1, 
136.5, 145.2, 149.1, 151.5, 155.4, 157.1, 162.5, 164.5, 
175.7; Anal. Calc: C21H15ClN4O3 (406.83): C, 62.0; H, 3.72; N, 






A solution of compound 9b (0.01 mol) and malononitrile 
(0.01 mol) in EtOH/DMF (15/5 mL) containing catalytic 
amount of piperidine was heated under reflux for 4 h. The 
solid was filtered off and recrystallized from ethanol/DMF 
as yellow crystals. Yield 76 %; IR: ν/cm–1 = 3437, 3343, 3228 
(NH2 & NH), 2931(CH-aliph), 2207(C≡N), 1656 (C=O); 1H 
NMR: δ/ppm = 4.15 (s, 2H, CH2), 5.54 (br, 2H, NH2), 7.00–8.25 
(m, 10H, Ar-H), 9.53 (br, 1H, NH cancelled with D2O); 13C NMR: 
43.1, 77.3, 110.4, 111.7, 112.4, 116.8, 118.8, 120.5, 121.2, 
123.9, 124.1, 129.5, 136.4, 142.0, 142.9, 145.1, 148.2, 153.8, 
155.4, 156.5, 156.9, 164.7; Anal. Calc. C24H15ClN6O3 (470.87): C, 






A solution of compound 9b (0.01 mol) and ethyl 
cyanoacetate (0.01 mol) in 20 mL (EtOH/DMF; 15/5 mL) 
containing catalytic amount of piperidine was heated under 
reflux for 5 h. The solid was filtered off and recrystallized 
from ethanol as brown crystals. Yield 72 %; m.p. 250–252 
°C; IR: ν/cm–1 = 3364 (broad, OH), 3228 (NH), 2945 (CH-
aliph), 2201 (C≡N), 1646 (C=O); 1H NMR: δ/ppm = 4.21 (s, 
2H, CH2), 7.51–8.60 (m, 10H, Ar-H), 9.2, 9.6 (2br, 2H, NH, 
OH cancelled with D2O); 13C NMR: 56.7, 110.8, 111.2, 112.8, 
113.4, 115.8, 120.4, 121.8, 123.4, 124.4, 130.2, 137.5, 
143.1, 146.2, 148.7, 151.8, 154.5, 156.0, 156.9, 165.4, 172; 
Anal. Calc. C24H14ClN5O4 (471.86): C, 61.09; H, 2.99; N, 
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